These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 29325898

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
    Till BG.
    Curr Treat Options Oncol; 2018 Jul 21; 19(9):45. PubMed ID: 30032463
    [Abstract] [Full Text] [Related]

  • 3. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
    Mondello P, Steiner N, Willenbacher W, Arrigo C, Cuzzocrea S, Pitini V, Mian M.
    Clin Lymphoma Myeloma Leuk; 2016 Feb 21; 16(2):82-8. PubMed ID: 26702476
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
    Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M, European Mantle Cell Lymphoma Network.
    Lancet; 2016 Aug 06; 388(10044):565-75. PubMed ID: 27313086
    [Abstract] [Full Text] [Related]

  • 6. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
    Tam CS, Khouri IF.
    Leuk Lymphoma; 2009 Aug 06; 50(8):1239-48. PubMed ID: 19562639
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL.
    Semin Oncol; 2002 Feb 06; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of older patients with mantle-cell lymphoma.
    Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH.
    N Engl J Med; 2012 Aug 09; 367(6):520-31. PubMed ID: 22873532
    [Abstract] [Full Text] [Related]

  • 11. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent Lymphomas (StiL).
    Lancet; 2013 Apr 06; 381(9873):1203-10. PubMed ID: 23433739
    [Abstract] [Full Text] [Related]

  • 12. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.
    Räty R, Honkanen T, Jantunen E, Jyrkkiö S, Karjalainen-Lindsberg ML, Kuittinen O, Lehto M, Mikkola M, Poikonen E, Rauhala A, Rimpiläinen J, Räsänen A, Siitonen S, Suominen M, Vapaatalo M, Elonen E.
    Leuk Lymphoma; 2012 Oct 06; 53(10):1920-8. PubMed ID: 22397313
    [Abstract] [Full Text] [Related]

  • 13. Clinical Management Updates in Mantle Cell Lymphoma.
    Chen R, Sanchez J, Rosen ST.
    Oncology (Williston Park); 2016 Apr 06; 30(4):353-60. PubMed ID: 27083466
    [Abstract] [Full Text] [Related]

  • 14. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
    Clin Adv Hematol Oncol; 2014 Aug 06; 12(8 Suppl 16):9-11. PubMed ID: 25768994
    [No Abstract] [Full Text] [Related]

  • 15. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
    Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcova P, Janikova A, Markova J, Obr A, Berkova A, Kubinyi J, Vaskova M, Mejstrikova E, Campr V, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M.
    Hematol Oncol; 2018 Feb 06; 36(1):110-115. PubMed ID: 29083050
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.